Traders News Source Issues Stocks on Watch and a New Feature Report

January 25, 2018 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Atossa Genetics Inc (NASDAQ: ATOS), BioPharmX Corporation (NYSE: BPMX), Avinger, Inc. (NASDAQ: AVGR) and Cytori Therapeutics, Inc. (NASDAQ: CYTX) and a feature report in one of the hottest sectors in the market.

Atossa Genetics Inc. (NASDAQ:ATOS) First quarter of 2018 Atossa Genetics Inc. will commence the Phase 2 Study of topical Endoxifen to treat mammographic breast density (or MBD) at Stockholm South General Hospital in Sweden. Defined Health, a leading market research firm, estimates that the potential market for Endoxifen exceeds $1 billion in annual sales. Atossa is a clinical-stage pharmaceutical company developing therapeutic and delivery methods to treat breast cancer.

Get our latest research on a highly-undervalued oil and gas company READ MORE
Copy and paste to your browser may be required to view the report – http://bit.ly/2BoBy1P-Feature-Report

BioPharmX Corporation (NYSE: BPMX) Acne patients may soon have another option, which some doctors call the “holy grail” of acne care: a truly safe and effective topical therapy expecting to launch phase three clinical trials for BPX-01 soon. Their focus is to develop products that treat health or age-related conditions that are not presently being addressed, treated or are treated with less than the highest standard drug therapies.

Avinger, Inc. (NASDAQ: AVGR) Avinger announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus Hospital in Münster, Germany, has successfully treated the first seven patients with a is a minimally invasive treatment designed by the next generation Avinger, Inc. atherectomy system. Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease.

Get our latest research on a highly-undervalued oil and gas company READ MORE
Copy and paste to your browser may be required to view the report – http://bit.ly/2BoBy1P-Feature-Report

Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently Cytori just announced completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial intended to study the safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects. They develop cell therapies that harness the unique traits of current living cells in adult patients to promote healing by using the company's own patented Celution System. Celution System is designed to repair injured tissue, preserve function, improve quality of life, and modify disease progression.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.

NOT FINANCIAL ADVICE
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Source: Traders News Source
Contact: editor@tradersnewssource.com

BioPharmX (AMEX:BPMX)
Historical Stock Chart
From Oct 2024 to Nov 2024